CA1151651A — Antitumor and immunosuppressive 4-carbamoyl imidazolium-5-olate derivatives, pharmaceutical composition and production thereof
Assigned to Sumitomo Chemical Co Ltd · Expires 1983-08-09 · 43y expired
What this patent protects
Abstract of the Disclosure There are provided compounds of the formula: wherein R is a heteroaroyl group containing a nitrogen, sulfur or oxygen atom which may be substituted with a lower alkyl group, an aralkyl group, an acyl group or a halogen atom; or…
USPTO Abstract
Abstract of the Disclosure There are provided compounds of the formula: wherein R is a heteroaroyl group containing a nitrogen, sulfur or oxygen atom which may be substituted with a lower alkyl group, an aralkyl group, an acyl group or a halogen atom; or a cycloalkanoyl group which may be substituted with a lower alkyl group, a lower alkenyl group, a halogen atom, a halogeno-lower alkenyl group, a phenyl group, a halogeno-phenyl group, a lower alkoxyphenyl group, a lower alkylphenyl group, a formyl group, a hydroxy group, an amino group, 2 carboxyl group, an amino methyl group or an oxo group, its non toxic salt and a process for producing them. Useful as antitumor agents and immunosuppressants.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.